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Targeting of retroviral vectors to specific cells has been attempted through engineering of the surface (SU) protein of the
murine leukemia viruses (MuLVs), but in many cases this has adversely affected protein function and targeted delivery has
been difficult to achieve. In this study, we have inserted a 15-mer peptide that binds specifically to the avb3 integrin into the
Moloney MuLV SU protein, including regions that are surface exposed in the crystal structure of the ecotropic receptor-
binding domain. We have concentrated in particular on the variable regions VRA, VRB, and VRC, which are responsible for
the use of distinct cellular receptors by different MuLV subtypes and therefore may be more likely to accommodate a
heterologous binding moiety. Despite these considerations, only 8 of 26 insertion sites were tolerated, including two separate
regions in VRA, a cluster of sites in VRC, and previously identified sites at the N-terminus of the protein and in the proline-rich
region immediately downstream of the receptor-binding domain. When expressed on retroviral vector particles, all of the
viable proteins retained the ability to bind to and transduce murine cells, although the VRC mutants and an insertion in VRA
gave reduced binding and titer. Finally, although all of the viable chimeras could bind to avb3 in a solid-phase binding assay,
we were unable to demonstrate expanded tropism for avb3-expressing human cells. This study highlights the difficulty of
engineering the Moloney MuLV SU protein, even when structural information is available, and provides guidelines for the
insertion of peptide ligands into the SU protein. © 2000 Academic Press
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lINTRODUCTION
The ability of retroviruses to integrate into the host cell
genome has led to the popularity of retroviral vectors in
gene transfer protocols where the stable introduction of
a therapeutic gene is required (Anderson, 1998). How-
ever, a major limitation to the clinical use of such vectors
is the lack of specificity of delivery to defined target cells.
Such targeted transduction would effectively increase
the titer of the vectors by preventing the transduction of
nontarget cells, and for toxic therapeutic gene products,
such as those proposed for certain anti-tumor strategies,
specific delivery would also minimize unwanted side
effects. Previous attempts to achieve targeted transduc-
tion have concentrated on the manipulation of the enve-
lope (Env) protein on the surface of the retroviral particle,
which interacts with a specific host cell surface receptor
and is the primary determinant of viral tropism (reviewed
in Hunter, 1997).
The murine leukemia virus (MuLV) Env is believed to
be a homotrimer (Kamps et al., 1991). Each monomer is
ynthesized as a single-chain precursor, Pr85, that is
ater processed into two subunits, the surface (SU) pro-
1 To whom correspondence and reprint requests should be ad-
ressed at Norris Cancer Center, Room 6338, USC School of Medicine,
441 Eastlake Avenue, Los Angeles, CA 90089. Fax: (323) 865-0097.
-mail: pcannon@hsc.usc.edu.
7ein and the transmembrane (TM) protein (Pinter and
onnen, 1983; Freed and Risser, 1987). The SU protein
ediates the attachment of the viral particle to its host
ell receptor, while the TM protein is required for the
embrane fusion events that occur after receptor bind-
ng (White, 1992). The SU protein can be divided into
hree regions: a variable N-terminal receptor-binding do-
ain (RBD) (Heard and Danos, 1991; Battini et al., 1995,
996; Davey et al., 1999), a more conserved C-terminal
omain that associates with the TM protein (Pinter and
leissner, 1977; Hunter, 1997), and a hypervariable pro-
ine-rich region (PRR) that links the two (Koch et al., 1983;
Ott et al., 1990; Wu et al., 1998). Within the N-terminal
RBD, amino acid sequence alignments have identified
three variable regions, designated VRA, VRB, and VRC,
which contain most of the sequence differences be-
tween the different MuLV subtypes and are primarily
responsible for the specificity of receptor interaction
(Battini et al., 1992; Fass et al., 1997).
Ecotropic MuLVs infect virtually all rodent cells but not
human cells. In order to develop a targeted retroviral
vector, a feasible approach is to expand the host range
of an ecotropic MuLV vector by introducing an additional
targeting moiety into Env (Cosset and Russell, 1996;
Schnierle and Gromer, 1996). At present, a common
strategy is the addition of a protein domain or single-
chain antibody (scFv) to the SU protein (Russell et al.,
0042-6822/00 $35.00
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8 WU ET AL.1993; Benedict et al., 1999; Zhao et al., 1999) or the
replacement of much of the RBD with such a ligand
(Kasahara et al., 1994). However, such approaches can
esult in lower levels of the chimeric Env being incorpo-
ated into viral particles when compared to the wild-type
rotein and coexpression of the wild-type protein may be
equired. In addition, the fusion capacity of chimeric Env
roteins is often dramatically impaired (Benedict et al.,
999; Zhao et al., 1999). As a result of these consider-
tions, we chose to use a small peptide ligand as a
argeting motif, expecting that this would be minimally
isruptive to the overall structure of the SU protein and to
rocesses such as transport to the cell surface, precur-
or processing, incorporation into particles, and fusion
ctivity.
In this study, a 15-amino-acid peptide that binds spe-
ifically to the vitronectin receptor, avb3 (Healy et al.,
1995), was inserted into the SU domain of the Moloney
MuLV (MoMuLV) Env, in particular at sites predicted to
be surface-exposed loops in the three-dimensional
structure of the monomer of the highly homologous
Friend MuLV (FrMuLV) RBD (Fass et al., 1997). Eight sites
in the receptor-binding domain of the SU protein were
identified that tolerated the insertion of the peptide, in-
cluding the region between residues 6 and 7, two sites in
VRA, a cluster of sites in VRC, and the PRR. In addition,
certain combinations of double insertions were also tol-
erated. Our analysis of the binding of the chimeric Env
FIG. 1. Peptide insertions in the MoMuLV RBD. (A) Amino acid seq
efined (Fass et al., 1997) are shaded. The proline-rich region (PRR) is
s is present in plasmid E/A-PRR used as the backbone for the inserti
hat generated viable chimeric Env proteins are arrowed. (B) Location o
n the crystal structure of the FrMuLV RBD (residues 9 to 236). Neither p
elative positions are estimated for illustrative purposes.proteins to avb3 in a solid-phase binding assay revealed
ifferences in their abilities, which may reflect the effectsf structural constraints from the surrounding Env protein
caffold on the accessibility and function of the targeting
eptide. Finally, the properties of the chimeric proteins
uggested that the VRC region may be important for
inding of Env to the ecotropic receptor, in addition to the
reviously identified VRA region (MacKrell et al., 1996;
avey et al., 1999), as insertions in VRC reduced both
inding to the ecotropic receptor and titer on murine NIH
T3 cells.
RESULTS
Rationale for selection of peptide insertion sites. Pre-
ious attempts to insert binding moieties into the Mo-
uLV Env protein have frequently met with the problem
hat the chimeric Env proteins generated were not effi-
iently processed and incorporated into retroviral parti-
les (Benedict et al., 1999). In order to increase our
hances of successfully inserting a targeting moiety into
he SU protein, we chose to use a small peptide rather
han a larger protein domain or scFv. The targeting pep-
ide used was a linear 15-amino-acid RGD peptide that
as previously been shown to preferentially bind to the
itronectin receptor, avb3 (Healy et al., 1995). For the
insertions in the SU protein, we selected sites predicted
to be surface exposed by the crystal structure of the
monomeric RBD of FrMuLV (Fass et al., 1997) and there-
fore more likely to tolerate such insertions. In particular,
of the N-terminus of the MoMuLV SU protein; VRA, VRB, and VRC as
nd the sequence shown is derived from the amphotropic Env protein,
is region (Wu et al., 1998). The locations of the peptide insertion sites
insertion sites in MoMuLV Env indicated by the homologous positions
6–7 nor position 265–266 is included in the crystal structure, but theiruence
boxed a
on in th
f viablewe chose to concentrate on the variable regions VRA,
VRB, and VRC (Fig. 1), as these regions naturally contain
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9PEPTIDE INSERTIONS IN MoMuLV SUsequence variation allowing the use of different recep-
tors and therefore may be more tolerant of the peptide
insertions. In addition, we also inserted the peptide into
two regions outside the RBD structure that have previ-
ously been shown to tolerate the insertion of binding
moieties: between amino acids 6 and 7 at the N-terminus
of SU (Russell et al., 1993; Benedict et al., 1999; Zhao et
l., 1999) and in the hypervariable PRR (Wu et al., 1998).
VRA (residues 50 to 115 in MoMuLV) consists of a
helical region (residues 97–110) that allows a more ex-
tended loop region to project away from the b-sandwich
ody of the RBD (Fass et al., 1997). Within this extended
egion there are two disulfide bonds that link cysteines
2 and 85, and 73 and 81, respectively (Linder et al.,
992), and that give rise to two cysteine-constrained
oops comprising residues 74–80 and 82–84. We have
reviously demonstrated that residues in the MoMuLV
RA are important for receptor binding, in particular
esidue D84 (MacKrell et al., 1996). Analysis of the struc-
ure of the region surrounding the equivalent aspartic
cid residue in the FrMuLV RBD has led to the sugges-
ion of a receptor-binding face that includes a charged
idge (equivalent MoMuLV residues R83, E87, P88, and
90) and a hydrophobic pocket (residues P88, L89, W100,
nd L92) (Fass et al., 1997). Accordingly, we made sev-
eral insertions in this region that we predicted would
place the RGD peptide at, or close to, the authentic
receptor-binding site. We replaced residues 74–80 and
74–84 in the cysteine-constrained loops with the RGD
peptide and also inserted the peptide at two positions
within these loops, between amino acids 78 and 79 and
amino acids 83 and 84. In addition, we made an insertion
between amino acids 91 and 92, close to the hydropho-
bic pocket. Finally, we also inserted the peptide between
residues 54 and 55, 59 and 60, and 69 and 70, which are
more distant from the putative receptor contact face but
are located in highly variable portions of the extended
VRA region, and also at sites 93–94 and 97–98, which are
located close to the VRA helix.
We also made several insertions at surface-exposed
sites in the VRC region (residues 120 to 130) and the VRB
region (residues 167 to 169). VRB has also been impli-
cated as a receptor-binding determinant for the MuLV
subtypes (Battini et al., 1995; Han et al., 1997), while VRC
as been suggested to be part of the putative ecotropic
eceptor-binding site by virtue of lying at the interface of
onomers in a computer-generated model of a trimer of
he FrMuLV RBD (Fass et al., 1997). Finally, we also
inserted the peptide into several regions that are con-
served between the different MuLV subtypes, but are
surface exposed in the RBD crystal structure.
Identification of sites that tolerate peptide insertions.
Twenty-six Env proteins containing peptide insertions
were generated and the chimeric proteins were as-
sessed for their ability to be processed and incorporated
into retroviral vectors (Table 1, Fig. 1). The majority of thepeptide insertions did not result in a functional Env pro-
tein that could be detected in retroviral particles and
analysis of cell lysates revealed that they were defective
in protein processing of the Env precursor, Pr85, to the
mature SU protein, gp70, indicating a block in the trans-
port pathway. However, several sites were identified that
did tolerate the peptide insertion, including site 6–7 at
the N-terminus of SU, sites 78–79 and 91–92 in the
extended coil of VRA, sites 125–126, 127–128, 128–129,
and 129–130 in the more exposed part of VRC, and
position 265–266 in the PRR.
Peptide insertions cause temperature-sensitive de-
fects in protein processing. We analyzed in more detail
TABLE 1
Peptide Insertions in MoMuLV SU
Insertion sitea Location in SUb Processingc Incorporationd
6–7 N-terminus 111 1
54–55 VRA 2 2
59–60 VRA 2 2
69–70 VRA 2 2
74–80 VRA 2 2
74–84 VRA 2 2
78–79 VRA 11 1
83–84 VRA 2 2
91–92 VRA 1 1
93–94 VRA 2 2
97–98 VRA 2 2
112–113 VRA 2 2
121–122 VRC 2 2
123–124 VRC 2 2
125–126 VRC 1 1
127–128 VRC 1 1
128–129 VRC 11 1
129–130 VRC 11 1
141–142 Conserved 2 2
150–151 Conserved 2 2
167–168 VRB 2 2
168–169 VRB 2 2
210–216 Conserved 2 2
212–213 Conserved 2 2
213–214 Conserved 2 2
265–266 PRR 111 1
a RGD peptide was inserted between amino acids (e.g., 6–7) or used
o replace amino acids (e.g., 74–84) of MoMuLV Env in plasmid pCEE1;
nsertion 256–266 was in plasmid E/A-PRR.
b VRA, VRB, and VRC regions vary in sequence between different
MuLV subtypes, while the N-terminus and the conserved regions do
not; PRR is the proline-rich region.
c Extent of Pr85 to SU protein processing in lysates of 293T cells at
37°C. 111, wild-type level of processing with more SU protein than
Pr85; 11, less SU protein than Pr85; 1, low level of processing; 2, only
Pr85 detected.
d SU protein present (1) or not (2) in retroviral vector particles
generated at 37°C.the form of the Env proteins present in cell lysates and
retroviral particles for the panel of viable chimeras. 293T
E
i
10 WU ET AL.cells were transfected with Env protein expression plas-
mids and Western blot analysis was performed on de-
glycosylated cell lysates in order to obtain a clearer
separation of Pr85, the SU protein, and possible process-
ing intermediates (Fig. 2A). In addition, retroviral particles
containing the chimeric Env proteins were partially puri-
fied through 20% sucrose and analyzed for the presence
of the SU protein (Fig. 2B).
The results revealed that the peptide insertions
caused varying effects on the efficiency of processing of
Pr85 to SU protein. Insertions at 6–7 and 265–266 re-
sulted in almost wild-type levels of Env processing, while
insertions at 78–79, 127–128, 128–129, and 129–130
caused a reduction in the efficiency of processing. The
insertions at sites 91–92 and 125–126 produced the most
seriously affected chimeras, as only trace amounts of the
mature form of the SU protein could be detected in the
cell lysates. In contrast to the results from the cell ly-
sates, the incorporation of chimeric Env proteins into
viral particles was efficient for all of the chimeras, with
the majority of the proteins being incorporated into viri-
ons at levels similar to the wild-type Env. Even for the
peptide insertions that resulted in poor protein process-
ing in the cell lysates, significant amounts of the SU
protein were still detected in the viral particles, although
the 91–92 insertion site resulted in the lowest levels of
SU protein detected.
Defects in protein processing, as observed for several
of the chimeric Env proteins, can reflect alterations in a
protein’s overall structure and folding pathway and such
FIG. 2. Western blot analysis of chimeric Env proteins produced at
37°C. (A) Cell lysates. Env proteins were expressed in 293T cells and
cell lysates were deglycosylated and probed with an anti-SU antibody.
Pr85 is the precursor form and SU is the mature processed form of Env.
Construct Pr85 contains a mutated SU–TM cleavage site and therefore
produces only Pr85, while construct SU is an Env protein prematurely
truncated at the SU-TM cleavage site and therefore expresses only SU.
The WT construct expresses the wild-type MoMuLV Env protein and
“Mock” is a transfection without any Env expression plasmid. (B) Viri-
ons. Viral particles were harvested from the supernatant of 293T cells
and partially purified by pelleting through 20% sucrose. The SU and
capsid (CA) proteins were detected with appropriate antibodies.defects are often less severe at lower temperatures.
Accordingly, we repeated the analysis of the Env proteinsat 32°C and observed that the processing of the chime-
ras and their subsequent incorporation into particles
were improved (Fig. 3). In particular, for the 91–92 chi-
mera, which displayed the most severe reduction in Env
processing at 37°C, the shift to the lower temperature
allowed near wild-type levels of processing and subse-
quent Env incorporation.
Interaction of chimeric Env proteins with the ecotropic
receptor. We investigated whether the chimeric Env pro-
teins still retained the capacity to interact with the eco-
tropic receptor. Retroviral vectors containing the chi-
meric proteins were produced at 37°C and titered on
NIH 3T3 cells, which express the ecotropic receptor. The
results (Table 2) revealed that the insertions at 6–7,
78–79, and 265–266 resulted in wild-type titers on NIH
3T3 cells, the insertions in VRC reduced titer by about
FIG. 3. Western blot analysis of Env proteins produced at 32°C.
Proteins were analyzed as described in the legend to Fig. 2. (A) Cell
lysates. All the chimeric proteins were processed efficiently from the
precursor form, Pr85, to the mature form, SU. (B) Virions.
TABLE 2
Characterization of Chimeric Env Proteins Containing
the RGD Peptide
Env protein Viral titer (CFU/ml)a Binding to NIH3T3 cellsb
Wild-type (1.3 6 0.3) 3 106 111
6–7 (1.8 6 0.9) 3 106 111
78–79 (1.5 6 0.5) 3 106 111
91–92 (3.4 6 2.3) 3 103 6
125–126 (1.4 6 1.6) 3 105 6
127–128 (2.4 6 2.7) 3 105 6
128–129 (2.2 6 0.2) 3 105 6
129–130 (2.5 6 1.1) 3 105 6
265–266 (2.0 6 0.1) 3 106 111
a Titer on NIH 3T3 cells of retroviral vectors pseudotyped by chimeric
nv proteins, produced at 37°C. Each titer value is the average of three
ndependent experiments 6 standard error.
b Binding of retroviral particles pseudotyped by the chimeric Env
proteins produced at 32°C to NIH 3T3 cells, as determined by FACScan
analysis. 111, wild-type level of binding; 6, only a trace amount of
binding was detected.
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11PEPTIDE INSERTIONS IN MoMuLV SUone order of magnitude, and the insertion at 91–92 re-
sulted in titers that were three orders of magnitude lower
than that of the wild-type.
To further analyze the ability of the chimeric Env pro-
teins to interact with the ecotropic receptor, we per-
formed an indirect immunofluorescence assay followed
by flow cytometry analysis in order to measure the ability
of the chimeric Env proteins to bind to NIH 3T3 cells
(Table 2). The viral particles used in the binding assay
were harvested at 32°C so that they would all contain
similar amounts of the chimeric Env proteins (Fig. 3). The
results were consistent with the titer data and revealed
that the Env proteins with insertions at sites 6–7, 78–79,
and 265–266 bound to NIH 3T3 cells at wild-type levels,
while the insertions at site 91–92 in VRA and at the
cluster of sites in the VRC region resulted in reduced
abilities to bind to the ecotropic receptor.
Accessibility of inserted peptides to an anti-RGD pep-
tide antibody. Although the peptide insertion sites we
had chosen were predicted to be surface exposed in the
monomeric RBD structure, their locations in an oligo-
meric Env protein complex may not be as accessible.
Accordingly, we wished to determine the extent to which
the peptides in the viable chimeras could be recognized
by an anti-peptide antiserum. The chimeric Env proteins
were expressed in 293T cells and the overall level of cell
surface Env was examined by flow cytometry using an
anti-SU monoclonal antibody, 83A25 (Evans et al., 1990).
he same cells were then examined for the ability of the
nv proteins to be recognized by the anti-peptide anti-
erum (Fig. 4).
Among the chimeric envelope proteins, 6–7, 78–79,
nd 265–266 had wild-type levels of cell surface expres-
ion, as detected by the anti-SU antibody. However, only
8–79 and 265–266 were also recognized by the anti-
GD peptide antibody, indicating good exposure of the
eptide ligand in these chimeras. The insertion at site
1–92 in VRA and all of the insertions in VRC resulted in
educed recognition by the anti-SU antibody, with the
29–130 chimera being particularly affected. Given the
ower levels of Env processing detected in the cell ly-
ates of these chimeric proteins (Fig. 2), it is highly likely
hat the lower levels of Env recognition by 83A25 re-
lected smaller amounts of Env proteins being expressed
n the cell surface. Although we cannot rule out the
ossibility that lower levels of Env were detected due to
nterference with the antibody recognition site by the
nserted peptide, we think that this is unlikely given that
3A25 recognizes an epitope downstream of the RBD
omain of the SU protein (Evans et al., 1990). Conse-
uently, for this group of chimeric proteins, we are not
ble to conclude whether their lack of recognition by the
ntiserum resulted from lower overall levels of cell sur-
ace expression or whether the peptides inserted at
hese locations were not readily available to the anti-
ody.
lMeasurement of the binding of chimeric Env proteins
o avb3. We used a solid-phase binding assay to mea-
sure the binding of the chimeric Env proteins to purified
integrin avb3. Retroviral vector particles were harvested
at 32°C to ensure good incorporation of each chimera. In
addition, the particles were harvested in serum-free me-
dium to minimize the amount of vitronectin in the viral
sample. Vitronectin is a natural ligand of avb3 (Felding-
abermann and Cheresh, 1993) and is present at high
FIG. 4. Recognition of Env proteins by anti-SU and anti-RGD peptide
antibodies. 293T cells were transfected by Env expression plasmids
and surface Env proteins were detected using FACS analysis. The
unshaded peaks represent cells that were stained with the secondary
antibodies only and the shaded peaks represent cells that were
stained with either the anti-SU antibody 83A25 (left) or the anti-RGD
peptide antiserum (right).evels in serum-containing medium.
The results of these analyses (Table 3) revealed that
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12 WU ET AL.insertion of the peptide at site 265–266 in the proline-rich
region resulted in the highest binding affinity, while in-
sertion at site 78–79 also resulted in a significant level of
binding. In contrast, insertions at positions 6–7, 91–92,
and 129–130 caused only low levels of binding to the
integrin. These results were in good agreement with the
data from the flow cytometry analyses that measured the
accessibility of the peptides to the anti-peptide anti-
serum (Fig. 4). Taken together, these data suggest that
peptides inserted at positions 78–79 in VRA and at 265–
266 in PRR are highly accessible on the surface of Env
and can bind to avb3. In contrast, the remaining insertion
sites do not allow the peptide to interact well with its
receptor. This could be due to poor exposure on the
surface of the Env protein complex, constraints imposed
by the surrounding protein sequences, or a combination
of both factors.
Interaction of peptide-containing Env proteins with hu-
man cells. We examined the ability of the chimeric Env
roteins to bind to a human melanoma cell line, M21, that
xpresses avb3 (Cheresh and Spiro, 1987) using indirect
immunofluorescence followed by flow cytometry analy-
sis. Except for the insertion at 265–266 that generated a
small mean-channel shift, the rest of the proteins did not
give a detectable binding signal (data not shown). We
further examined whether retroviral vectors expressing
the chimeric envelope proteins could transduce either
M21 or MG-63 cells. Although vectors containing the
amphotropic MuLV envelope protein gave titers of 4–6 3
104 colony-forming units (CFU)/ml on these cells, no
etectable titer was observed for any of the viable chi-
eric Env proteins.
Simultaneous peptide insertions in two locations of SU
rotein. A short peptide ligand usually has only a modest
ffinity for its receptor, and this can be further reduced if
he peptide is inserted into a heterologous protein. We
herefore investigated the possibility of increasing the
TABLE 3
Binding of Chimeric Env Proteins to Integrin avb3
Envelope protein Binding to avb3 receptor
a
Mock 0.016 6 0.009
Wild-type 0.036 6 0.001
6–7 0.106 6 0.013
78–79 0.268 6 0.018
91–92 0.124 6 0.008
129–130 0.152 6 0.008
265–266 0.552 6 0.027
a Binding capacity of the chimeric Env proteins to integrin avb3 was
estimated by a solid-phase binding assay; the numbers represent the
optical density at 490 nm, measuring the amount of Env protein re-
maining associated with the avb3-coated plate. Each value is the mean
f two independent experiments.ffinity of the chimeric Env proteins for avb3 by inserting
the peptide simultaneously into two locations in the SUprotein. Various combinations of insertions in the sites
previously identified as viable were constructed and the
resulting Env proteins were assessed by Western anal-
ysis of retroviral particles and by examining their ability
to transduce NIH 3T3 cells (Fig. 5). Just as the single
insertions at positions 6–7, 78–79, and 265–266 had no
effect on viral titer (Table 2), we also found that the
various combinations of these three insertion sites gave
rise to fully functional Env proteins. The single insertion
of a peptide at position 129–130 had previously reduced
the titer on NIH 3T3 cells by one order of magnitude
(Table 2) and the combination of 129–130 with any of
these three innocuous insertion sites also resulted in
chimeric proteins that gave similarly reduced titers.
Overall, we found that there was no strict correlation
between the efficiency of incorporation of the chimeric
Env proteins into viral particles and subsequent titer on
NIH 3T3 cells.
We also assessed whether any of the double-peptide
insertions resulted in higher binding affinity for the avb3
receptor using the solid-phase binding assay. The re-
sults revealed that the combination of insertions at po-
sitions 265–266 and 78–79 gave rise to the highest level
overall of binding (Table 4). However, despite any im-
proved affinity for the avb3 integrin, we were still unable
o demonstrate transduction of M21 cells for any of the
ouble-insertion chimeras (data not shown).
Taken together, these results indicate that peptide
nsertions are well tolerated at combinations of sites 6–7,
8–79, and 265–266, which can be used to generate
ultivalent chimeric Env proteins that retain full function
n cells expressing the ecotropic receptor. Furthermore,
he combination of the 78–79 insertion site with 265–266
nhanced the overall affinity of the chimeric Env protein
or the avb3 integrin target receptor.
FIG. 5. Chimeric Env proteins with double-peptide insertions in the
SU protein. Retroviral vectors expressing chimeric Env proteins were
produced at 37°C and analyzed by Western blotting, as described in
the legend to Fig. 2. The retroviral vectors were titered on NIH 3T3 cells,
as shown at the bottom of the figure.
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13PEPTIDE INSERTIONS IN MoMuLV SUDISCUSSION
We have undertaken a comprehensive screen to iden-
ify sites in the RBD of the MoMuLV Env protein that can
ccommodate the insertion of a targeting peptide. The
hoice of sites was based on consideration of the three-
imensional structure of the highly homologous RBD of
rMuLV (Fass et al., 1997), together with data from pre-
ious attempts to engineer MoMuLV Env (Russell et al.,
993; Wu et al., 1998). A 15-amino-acid RGD-containing
eptide was inserted into various locations in the SU
rotein predicted to be surface exposed in the RBD
onomer and therefore considered more likely to toler-
te such insertions. The majority of sites chosen resided
n the three variable regions of VRA, VRB, and VRC, which
aturally vary in sequence between the different MuLV
ubtypes and are the major determinants of receptor
hoice (Battini et al., 1992). Furthermore, we concen-
rated in particular on regions surrounding the predicted
eceptor-binding site in the VRA of the ecotropic Env
MacKrell et al., 1996; Fass et al., 1997). Despite these
considerations, the majority of the peptide insertions we
made resulted in chimeric Env proteins that were not
properly processed or able to be incorporated into viral
particles. These results emphasize the difficulties inher-
ent in engineering a complex oligomeric protein, even
when structural information is available.
Eight sites were identified that did tolerate the inser-
tion of the RGD peptide. At the N-terminus of the protein,
an insertion between amino acids 6 and 7 resulted in an
Env protein that retained wild-type function when incor-
porated into retroviral vectors. The N-terminus of the SU
TABLE 4
Binding of Chimeric Env Proteins with Double-Peptide Insertions
to Integrin avb3
Env protein
Binding to avb3
a
Experiment I Experiment II
wt 0.101 ND
6–7 0.30 0.348
78–79 0.336 0.508
91–92 0.337 0.260
129–130 0.24 0.174
265–266 0.924 0.902
6–7/78–79 0.391 0.426
6–7/129–130 0.294 0.252
6–7/265–266 0.890 1.161
78–79/129–130 0.225 0.488
78–79/265–266 1.314 1.059
129–130/265–266 0.260 0.596
a Binding of Env proteins to integrin avb3 was estimated by a solid-
phase binding assay. The numbers represent the optical density at 490
nm. The results from two independent experiments are shown.protein, and in particular residue H8, is important for
postbinding functions (Bae et al., 1997; Burke et al., in
d
ipreparation; Zavorotinskaya and Albritton, 1999) and al-
though single-chain antibodies can be inserted at this
site (Russell et al., 1993; Benedict et al., 1999; Zhao et al.,
999), the resulting chimeras frequently have impaired
unction. The retention of wild-type function by the 6–7
nsertion indicates the advantage of using small peptide
nsertions over larger targeting ligands.
We made several insertions in the VRA region as we
easoned that the use of the presumed authentic recep-
or-binding site would be more likely to trigger the sub-
equent downstream events necessary to catalyze
irus–cell fusion. VRA contains an extended region that
rojects away from the body of the protein and consists
f two loops (MoMuLV residues 73–81 and 89–96), sep-
rated by a small helix (residues 83–87) (Fass et al.,
997) that contains the key receptor-binding residue, D84
MacKrell et al., 1996). Although no individual residues in
he extended VRA region (apart from the structurally
mportant cysteines) have been identified that interfere
ith Env processing (MacKrell et al., 1996; Davey et al.,
1998), the replacement of residues 74–80 or 74–84 by the
peptide was not tolerated. In contrast, we observed that
the peptide could successfully be inserted between res-
idues 78 and 79, which is at the apex of this region and
extends about 9 Å from the body of the protein. At other
sites in VRA, we found that an insertion between resi-
dues 83 and 84, which would place the peptide directly
at the predicted receptor-binding face, was not tolerated.
In contrast, a site in the second loop region of VRA
between amino acids 91 and 92 that tolerated the inser-
tion of the peptide was identified, although the effects of
this insertion on both titer and binding to NIH 3T3 cells
suggest that the inserted peptide could be blocking the
receptor-binding site. Indeed, residue L92 is part of the
hydrophobic pocket predicted to be part of the receptor-
binding surface in the ecotropic Env (Fass et al., 1997).
We also identified a cluster of sites in VRC (residues
125–130) that tolerated the insertion of the peptide, al-
though the resulting Env proteins were defective in bind-
ing to the ecotropic receptor. These observations were
somewhat unexpected given the distance of this region
from the presumed receptor-binding site and the lack of
any previous data from mutagenesis studies implicating
this region (MacKrell et al., 1996; Burke et al., in prepa-
ation). However, it has been suggested that VRC might
articipate in a receptor-binding site formed by oli-
omers of the Env protein and a speculative structure of
possible RBD trimer places VRC from one monomer
lose to VRB in an adjacent monomer (Fass et al., 1997).
urthermore, the location of VRC at a subunit interface
ay explain why these insertions adversely affected the
rocessing of Env.
The final site that we identified that could tolerate
eptide insertions was in the PRR. We have previously
emonstrated that a collagen-binding peptide could be
nserted here without adversely affecting Env function
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14 WU ET AL.(Wu et al., 1998) and we now extend those findings to
emonstrate that a different peptide can also be toler-
ted. In addition, a recent report from Kayman et al.
1999) has demonstrated that the PRR can also tolerate
he insertion of an scFv, indicating the general utility of
his site for peptide insertions. Peptides inserted at dif-
erent sites in Env bound to avb3 with different affinities,
onsistent with their different abilities to be recognized
y an anti-peptide antibody and presumably correspond-
ng to the extent of their surface exposure. The PRR
nsertion (265–266) displayed the highest level of binding
nd had the greatest recognition by the anti-peptide
ntibody. The formation of a relatively extended structure
n the PRR has been suggested (Fontenot et al., 1994),
hich could account for these properties.
Overall, our data suggest that the sites in the SU
rotein most able to tolerate a peptide insertion are
ocated in regions of the protein that do not interact
xtensively with the rest of the SU protein. Residues 78
nd 79 and 125 to 130 are located in regions that pro-
rude from the RBD core by about 9 to 10 Å, and while the
xact positioning of the 6–7 and 265–266 insertion sites
s unknown, it is likely that they are also in more flexible
egions, distant from the core of the envelope protein.
aken together, this indicates that exposure on the pro-
ein surface may be insufficient to create an optimal
eptide insertion site, but that a lack of interaction with
he body of the protein may also be required.
Some of the chimeric envelope proteins, especially
hose with insertions in the VRC region, showed very
imited levels of binding to NIH 3T3 cells but retained a
igh level of infectivity when titered on NIH 3T3 cells. It
s likely that this apparent discrepancy merely reflects
he lower sensitivity of the binding assay than the titer
ssay. Alternatively, it is also possible that peptide inser-
ions in these regions affected the ability of the anti-Env
ntibody to recognize the chimeric envelope proteins
ithout inhibiting envelope protein function. In addition,
ome of the fusion proteins, such as 78–79, 91–92, and
25–126, were poorly processed in cells, yet were effi-
iently incorporated into virions. It is likely that the high
evel of envelope proteins resulting from our transfection
rocedure allows sufficient processed envelope proteins
o reach the cell surface and to be incorporated into viral
articles, despite these defects.
We attempted to transduce the M21 human melanoma
ell line, which expresses high levels of avb3, with the
chimeric Env proteins. Although vectors expressing the
amphotropic MuLV Env protein transduced these cells
reasonably efficiently, none of the chimeric Env proteins
were able to transduce the M21 cells. There are two
possibilities to account for this lack of success. First, the
ability of the peptides to bind to avb3 may not be suffi-
ient to allow efficient transduction. The peptide ligand
lone has only a modest affinity for avb3, with an esti-
ated IC50 of around 400 nm (Healy et al., 1995), and
s
cdditional constraints in the context of the ecotropic Env
ackbone might be expected to further interfere with its
inding ability. Indeed we were unable to demonstrate
inding to M21 cells for any of the chimeras except for
he 265–266 insertion. Alternate approaches that may
roduce better results include the use of higher affinity
igands or by flanking the ligands with cysteine residues
o facilitate a more exposed and constrained structure
hrough disulfide-bond formation. However, even if high-
ffinity binding could be obtained, it remains a distinct
ossibility that this will not lead to the fusion of viral and
ellular membranes. Indeed, we have previously demon-
trated that the block to transduction for chimeric Env
roteins containing insertions of scFvs is due to the
nability of the scFv–receptor interaction to trigger the
nv protein to a fusogenic state (Benedict et al., 1999;
hao et al., 1999).
Nevertheless, the sites in the SU protein that we have
dentified that tolerate the insertion of a targeting peptide
ay have utility for targeting retroviral vectors through
lternate approaches, such as “tethering” strategies.
ere, the role of the targeting peptide is to concentrate
he vectors at a specific target tissue, with entry subse-
uently proceeding through the natural Env–receptor in-
eraction. We have previously demonstrated the utility of
his approach in rodent cells using collagen-targeted
cotropic Env proteins (Hall et al., 1997).
MATERIALS AND METHODS
Cell lines. 293T cells were obtained from the American
ype Culture Collection (ATCC) (CRL 11268). NIH 3T3 and
93T cells were maintained in Dulbecco’s modified Ea-
le’s medium, supplemented with 10% fetal calf serum
FCS) (HyClone, Logan, UT) and 2 mM glutamine (Gibco
RL, Grand Island, NY). The M21 cell line (Cheresh and
piro, 1987) is a human melanoma cell line kindly pro-
ided by Dr. Peter Brook (University of Southern Califor-
ia). The cells were propagated in RPMI 1640 medium
Gibco BRL), supplemented with 10% FCS and 2 mM
lutamine. MG-63 cells (ATCC, CRL-1427) are a human
steosarcoma cell line (Stuvier et al., 1996) and were
maintained in minimal essential medium supplemented
with nonessential amino acids (Gibco BRL) and 10% FCS.
Envelope protein expression plasmids. Plasmid
pCEE1 is an expression plasmid for the MoMuLV eco-
tropic envelope protein (MacKrell et al., 1996); plasmid
/A-PRR is an expression plasmid for MoMuLV Env but
ith the PRR sequence replaced by the amphotropic
070A MuLV sequence (Wu et al., 1998). The 15-amino-
cid peptide sequence GERGDGSFFAFRSPF (Healy et
l., 1995) was inserted into various positions in the en-
elope protein by recombinant PCR splice overlap exten-
ion (Ho et al., 1989). All chimeric Env proteins were
onfirmed by DNA sequencing.
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15PEPTIDE INSERTIONS IN MoMuLV SURetroviral vector production. Retroviral vectors were
produced by transient transfection of 293T cells with the
MoMuLV Gag-Pol expression plasmid pHIT60 (Soneoka
et al., 1995), the retroviral vector pCnBg (Han et al., 1997),
which expresses LacZ and neor, and an Env expression
lasmid, essentially as described (Soneoka et al., 1995).
ransfection was carried out by the calcium phosphate
recipitation method, using a calcium phosphate mam-
alian cell transfection kit (5Prime3 3Prime, Inc., Boul-
er, CO). Approximately 16 h posttransfection, the pre-
ipitate was removed, and medium containing 10 mM
odium butyrate (Sigma, St. Louis, MO) was added to the
ells for 10 h. The cells were then incubated for a further
2 h in fresh medium at 37°C, or for 48 h at 32°C, before
he culture supernatant was harvested. Retroviral vectors
ere also produced in serum-free medium at 32°C by
ncubation in IS 293 (Irvine Scientific) after the sodium
utyrate treatment. Vector supernatants were filtered
hrough 0.45-mm filters and either used immediately or
stored at 270°C.
Titer determination. Vector titer on NIH 3T3 cells was
determined by scoring the number of 5-bromo-4-chloro-
3-indolyl-b-D-galactopyranoside (X-Gal)-positive foci fol-
owing transduction of the cells. NIH 3T3 cells (3 3 104)
ere seeded in 3 ml of medium per 30-mm well in
ix-well plates and 18 h later, the medium was replaced
ith 1 ml of appropriately diluted viral supernatant con-
aining polybrene (8 mg/ml) (Sigma) and incubated for 2 h
t 37°C. An additional 2 ml of medium was then added,
nd the cultures were incubated for another 48 h, after
hich the cells were stained by X-gal to detect b-galac-
osidase expression as previously described (MacKrell
t al., 1996) and the number of blue colonies was deter-
ined. Titer was expressed as colony-forming units per
illiliter.
Vector titer on human cells was determined by scoring
he number of neomycin-resistant colonies. High-level
xpression of the avb3 integrin on the cell surface of the
M21 and MG-63 cell lines was confirmed by fluores-
cence-activated cell sorting (FACS) analysis using mono-
clonal antibody LM609 (Chemicon, Temecula, CA). The
cells were seeded at 3 3 104 cells per 30-mm well in
six-well plates and 18 h later the medium was removed
and the cells were incubated in IS 293 medium at 37°C
for 20 min. The cells were then incubated with viral
supernatants harvested at 32°C in IS 293 medium in the
presence of 4 mg/ml protamine sulfate (Sigma) for 3 h
before the addition of 2 ml RPMI 1640 medium. Twenty-
four hours later, the medium was replaced with fresh
medium containing 0.5 mg/ml of G418 (Gibco BRL) in
order to select for transductants. Viral titer was scored by
the number of neomycin-resistant colonies established
after 10 days of selection.
Western blot analysis of Env proteins. Retroviral parti-
cles generated by transient transfection of 293T cells
were pelleted through 20% sucrose at 16,000 g, 4°C for30 min. Viral pellets were resuspended in 30 ml of 23
SDS gel loading buffer (100 mM Tris–HCl, pH 6.8, 4%
SDS, 20% glycerol, 0.01% bromphenol blue, 1.4 M b-mer-
captoethanol) and boiled for 5 min. Viral protein samples
were resolved on a precast 8–16% polyacrylamide gel
(Novex, San Diego, CA) and transferred onto an Immo-
bilon membrane (Millipore, Bedford, MA). The blot was
blocked overnight at 4°C in 5% powdered milk in TBS
buffer (50 mM Tris–HCl, pH 7.5, 150 mM NaCl, 0.25%
Tween 20) and incubated with primary antibodies at
room temperature for 2 h. After being washed in TBS
buffer for 30 min, blots were incubated with secondary
antibodies for 1 h at room temperature followed by a
further 30-min washing in TBS. Specific proteins were
visualized using the ECL detection system (Amersham
International plc., Arlington Heights, IL). The primary an-
tibodies used were goat anti-Rauscher MuLV gp69/71,
1:3000 dilution (Quality Biotech, Camden, NJ; Lot
79S656); goat anti-Raucher MuLV p30, 1:10,000 dilution
(Quality Biotech, Lot 78S221), and rat anti-AKR MuLV
p15E, 1:2000 dilution (BABCO, Berkeley, CA, Lot 42/114)
(Pinter and Fleissner, 1977). The secondary antibodies
were horseradish peroxidase (HRP)-conjugated rabbit
anti-goat immunoglobulin G (IgG) (1:10,000) and HRP-
conjugated goat anti-rabbit IgG (1:10,000) (Pierce, Rock-
ford, IL).
To analyze the form of the envelope proteins present
in cell lysates, 293T cells were transfected with enve-
lope protein expression plasmids alone (30 mg per
10-cm plate) and lysates were prepared by incubating
the cells in 500 ml lysis buffer (20 mM Tris–HCl, pH 7.5,
% Triton X-100, 0.05% SDS, 5 mg/ml sodium deoxy-
holate, 150 mM NaCl, and 1 mM phenylethanolamine
luoride) for 10 min at 4°C, followed by centrifugation
t 10,000 g for 10 min to pellet nuclei. Envelope pro-
eins were denatured by treating the lysates with 0.5%
DS and 1% b-mercaptoethanol at 100°C for 5 min and
hen deglycosylated with 50 mM sodium phosphate
pH 7.5), 1% NP-40, and 500 units N-glycosidase F
New England Biolabs, Beverly, MA) at 37°C for 1 h.
nvelope proteins were detected by Western blotting
s described above.
Flow cytometry analysis of Env proteins on cell sur-
ace. Env protein on the cell surface was measured by
ACS of 293T cells that transiently expressed the wild-
ype or chimeric Env proteins. 293T cells in a 10-cm plate
ere transfected with 30 mg of envelope protein expres-
sion plasmid and 48 h later the cells were harvested with
trypsin-free cell dissociation buffer (Gibco BRL). The
cells were washed with 10% goat serum in phosphate-
buffered saline (PBS), followed by incubation for 1 h at
4°C with 250 ml of undiluted hybridoma supernatant
containing monoclonal antibody 83A25 (Evans et al.,
1990). After incubation, the cells were washed again and
resuspended in 100 ml of 1:100-diluted fluorescein iso-
thiocyanate (FITC)-labeled goat anti-rat IgG (Kirkegaard
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16 WU ET AL.& Perry Laboratories, Inc., Gaithersburg, MD) for contin-
ued incubation for 1 h at 4°C. Cells were then washed
and fixed in 4% paraformaldehyde in PBS. The level of
envelope protein expression on the cell surface was
estimated by measuring the fluorescence intensity of the
samples with a FACStar Plus flow cytometer (Becton
Dickinson, San Jose, CA).
Flow cytometry analysis was also used to examine the
accessibility of the inserted RGD peptide to antibody. The
chimeric Env proteins were expressed on the surface of
293T cells as described above and the cells were incu-
bated with a rabbit antiserum raised against the RGD
peptide (derived by Zymed, San Francisco, CA). The
secondary antibody used was FITC-labeled goat anti-
rabbit IgG (Kirkegaard & Perry Laboratories, Inc.).
Binding of viral particles to NIH 3T3 cells. To measure
the binding of viral particles to NIH 3T3 cells, the cells
were dissociated by trypsin treatment and washed in
10% goat serum in PBS, and 5 3 105 cells were mixed
with 1 ml of retroviral vector supernatant (harvested at
32°C) and incubated at 4°C for 2 h with gentle rotation.
The cells were then washed in 10% goat serum in PBS
twice and the bound viral particles were detected by flow
cytometry analysis, as described above for the detection
of cell surface Env.
Solid-phase binding assay. Plastic 96-well plates were
coated with avb3 integrin (1 mg/ml) (Chemicon, Te-
ecula, CA) by being incubated in coating buffer (20 mM
ris–HCl, 150 mM NaCl, 0.5 mM CaCl2, 1.0 mM MgCl2, 1.0
mM MnCl2, pH 7.5) overnight at 4°C. The wells were
washed twice with PBS and blocked with 1% casein
(Sigma) in PBS at 37°C for 1 h and then washed twice
with binding buffer (50 mM Tris–HCl, 150 mM NaCl, 0.05
mM CaCl2, 1.0 mM MgCl2, 1.0 mM MnCl2, pH 7.5). Viral
particles were collected in serum-free medium at 32°C,
purified by pelleting through 20% sucrose, and resus-
pended in 50 ml binding buffer. This was added to the
wells and incubated for 1 h at room temperature. After
two washes with binding buffer, the bound viral particles
were detected by an ELISA. In brief, the wells were
incubated with a 1:5 dilution of rat monoclonal antibody
83A25 in 0.5% casein (w/v) at 37°C for 1 h. After being
washed twice in washing buffer (10 mM Tris–HCl, pH 8.0,
138 mM NaCl), the wells were incubated with HRP-
conjugated goat anti-rat IgG diluted 1:2000 in 0.5% ca-
sein at 37°C for 1 h and then washed twice with washing
buffer. Finally, 50 ml of o-phenylenediamine dihydrochlo-
ide in 24 mM citric acid and 50 mM dibasic sodium
hosphate was added to the wells, and the color was
llowed to develop for 5 min at room temperature and
topped by the addition of 25 ml of 4 M hydroxy sulfate.
The color was monitored at 490 nm with an Emax pre-
cision microplate reader (Molecular Devices, Sunnyvale,
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